Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 4/2011

01.08.2011

Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

verfasst von: Vladimir Lerner, Chanoch Miodownik

Erschienen in: Current Psychiatry Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Abnormal involuntary dyskinetic movements in schizophrenia patients have been documented for more than 140 years. Clinicians should distinguish between two kinds of disturbances—spontaneous dyskinetic movements and movements induced by psychotropic medications—which may look familiar clinically. As a modern term, tardive dyskinesia (TD) is a potentially permanent neurological hyperkinetic movement disorder that occurs after months or years of taking psychotropic drugs. Several distinct forms of TD exist, specifically tardive akathisia, tardive blepharospasm, tardive dystonia, tardive gait, tardive myoclonus, tardive tremor, and tardive tics, and they have different pathophysiologies and treatment. The pathogenesis of TD remains unclear, and the pathophysiology is complex and multifactorial. Moreover, there is solid evidence of a genetic predisposition to TD. This article summarizes recent relevant publications concerning TD and the most recent studies regarding treatment of this disorder with antioxidative agents.
Literatur
1.
Khot V, Wyatt RJ. Not all that moves is tardive dyskinesia. Am J Psychiatry. 1991;148:661–6.PubMed
2.
Owens DGC. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge: Cambridge University Press; 1999.CrossRef
3.
Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61 Suppl 4:10–4.PubMed
4.
Waddington JL, Crow TJ. Abnormal involuntary movements and psychosis in the preneuroleptic era and in medicated patients: implications for the concept of tardive dyskinesia. In: Wolf ME, Mosnaim AD, editors. Tardive dyslinesia: biological mechanisms and clinical aspects. Washington: American Psychiatric Press; 1988. p. 51–66.
5.
Crow TJ, Cross AJ, Johnstone EC, et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol. 1982;2:336–40.PubMedCrossRef
6.
Kraepelin E. Dementia praecox and paraphrenia. Barclay, M. (trans). Huntington: Krieger, 1971.
7.
Fish F. Leonhard’s classification of schizophrenia. J Ment Sci. 1958;104:943–71.PubMed
8.
Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28:550–3.PubMed
9.
Sigwald J, Bouttier D, Raymondeaud C, Piot C. 4 cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics. Rev Neurol (Paris). 1959;100:751–5.
10.
Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964;40:10–27.PubMedCrossRef
11.
Detweiler MB, Kalafat N, Kim KY. Drug-induced movement disorders in older adults: an overview for clinical practitioners. Consult Pharm. 2007;22:149–65.PubMedCrossRef
12.
Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am. 2005;28:255–74. x.PubMedCrossRef
13.
Brion S, Plas J, Chevalier JF, Dussaux P. Senile dyskinesias and tardive dyskinesias. Encephale 1988;14 Spec No:215–219
14.
Lauterbach EC, Carter WG, Rathke KM, et al. Tardive dyskinesia—diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service. Schizophr Bull. 2001;27:601–13.PubMed
15.
Skidmore F, Weiner WJ, Burke R. Neuroleptic-induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell; 2005. p. 257–84.CrossRef
16.
DeLeon ML, Jankovic J. Clinical features and management of tardive dyskinesias, tardive myoclonus, tardive tremor, and tardive tourettism. In: Sethi K, editor. Drug induced movement disorders. New York: Marcel Dekker, Inc.; 2004. p. 77–109.
17.
Lerner V, Libov I, Kaptsan A, et al. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;44:20–8.PubMed
18.
19.
Miodownik C, Lerner V, Witztum E. Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. Isr J Psychiatry Relat Sci 2011 (in press).
20.
21.
22.
Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone, Elsevier; 2007.
23.
van Harten PN, Matroos GE, Van Os J. The course of tardive dystonia in Afro Caribbean patients, a population-based study: the Curacao extrapyramidal syndromes study: VII. Schizophr Res. 2008;98:79–83.PubMedCrossRef
24.
Lee Y, Yeh WC, Chong MY, et al. Venlafaxine and tardive blepharospasm: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1139–40.PubMedCrossRef
25.
Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J Neuropsychiatry Clin Neurosci. 2007;19:86–7.PubMedCrossRef
26.
27.
Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura; 1992. p. 167–98.
28.
Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–51.PubMedCrossRef
29.
30.
31.
32.
Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61 Suppl 4:5–9.PubMed
33.
Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. 2007;153:271–5.PubMedCrossRef
34.
Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet. 2009;19:106–7.PubMedCrossRef
35.
• Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 2009; 11: 405–415. This is a review regarding the effect of dopamine D2- and D3-receptor genes (DRD2, DRD3, and HTR2C) on the risk of TD.PubMed
36.
Souza RP, Remington G, Chowdhury NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol. 2010;20:688–94.PubMedCrossRef
37.
Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003;39:19–49.CrossRef
38.
Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry. 2006;18:133–43.PubMedCrossRef
39.
Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1130–8.PubMedCrossRef
40.
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68:1648–54.PubMedCrossRef
41.
Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:1031–7.PubMedCrossRef
42.
Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res. 2005;74:263–70.PubMedCrossRef
43.
Dalgalarrondo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci. 1994;244:272–7.PubMedCrossRef
44.
Bai YM, Chou KH, Lin CP, et al. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study. Schizophr Res. 2009;109:167–81.PubMedCrossRef
45.
McCreadie RG, Thara R, Padmavati R, et al. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry. 2002;59:332–6.PubMedCrossRef
46.
Niznikiewicz MA, Kubicki M, Shenton ME. Recent structural and functional imaging findings in schizophrenia. Curr Opin Psychiatry. 2003;16:123–47.CrossRef
47.
Szymanski S, Gur RC, Gallacher F, et al. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism. Neuropsychopharmacology. 1996;15:567–75.PubMedCrossRef
48.
Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia: shortened left caudate T2. Biol Psychiatry. 1990;28:1027–36.PubMedCrossRef
49.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151–6.PubMedCrossRef
50.
Tenback DE, van Harten PN, Slooff CJ, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010;24:1031–5.PubMedCrossRef
51.
DeLeon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia. A naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2007;257:169–72.CrossRef
52.
•• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010; 71: 463–474. This prospective cohort study found that current users of typical and atypical antipsychotics had similar incidences of TD. PubMedCrossRef
53.
Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98.PubMedCrossRef
54.
Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–312.PubMedCrossRef
55.
Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11:169–82.PubMedCrossRef
56.
Fehr C, Dahmen N, Klawe C, et al. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001;21:248–9.PubMedCrossRef
57.
Kabes J, Sikora J, Stary O, et al. Effectiveness of piracetam in tardive dyskinesia—double-blind cross-over controlled trial with a placebo. Cesk Psychiatr. 1983;79:339–45.PubMed
58.
59.
Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol. 2006;26:215–6.PubMedCrossRef
60.
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21:1219–21.PubMedCrossRef
61.
Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546–54.PubMedCrossRef
62.
Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65 Suppl 9:25–8.PubMed
63.
Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42:281–5.PubMedCrossRef
64.
Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev. 2011;33:289–93.PubMedCrossRef
65.
Schaeffer MC, Cochary EF, Sadowski JA. Subtle abnormalities of gait detected early in vitamin B6 deficiency in aged and weanling rats with hind leg gait analysis. J Am Coll Nutr. 1990;9:120–7.PubMed
66.
Dakshinamurti K, Paulose CS, Viswanathan M, et al. Neurobiology of pyridoxine. Ann NY Acad Sci. 1990;585:128–44.PubMedCrossRef
67.
Goodman LS, Gilman A. The pharmacologic basis of therapeutics, vol. II. 8th ed. New York: McGraw-Hill; 1992.
68.
Dreyfus PM, Geel SE. Vitamins and nutritional deficiencies. In: Siegel GJ, Alberts RW, Agranoff BW, Katzman R, editors. Basic neurochemistry. Boston: Little Brown; 1981. p. 661–79.
69.
Viswanathan M, Siow YL, Paulose CS, Dakshinamurti K. Pineal indoleamine metabolism in pyridoxine-deficient rats. Brain Res. 1988;473:37–42.PubMedCrossRef
70.
Cabrini L, Bergami R, Fiorentini D, et al. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int. 1998;46:689–97.PubMed
71.
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158:1511–4.PubMedCrossRef
72.
Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47–62.PubMedCrossRef
73.
74.
Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry. 1998;43:868–72.PubMedCrossRef
75.
Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57:167–73.PubMed
76.
Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836–41.PubMedCrossRef
77.
Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry. 1992;149:391–3.PubMed
78.
Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry. 1997;41:114–6.PubMedCrossRef
79.
Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacother. 1999;33:1195–202.PubMedCrossRef
80.
Barak Y, Swartz M, Shamir E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry. 1998;10:101–5.PubMed
81.
Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001:CD000209.
82.
Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61:835–45.PubMedCrossRef
83.
Reiter RJ, Maestroni GJ. Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. J Mol Med. 1999;77:36–9.PubMedCrossRef
84.
Shamir E, Barak Y, Plopsky I, et al. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry. 2000;61:556–8.PubMedCrossRef
85.
Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58:1049–52.PubMedCrossRef
86.
87.
Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother. 2003;37:1128–31.PubMedCrossRef
88.
Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J Neurochem. 2000;74:2268–77.PubMedCrossRef
89.
DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25–58.PubMedCrossRef
90.
Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001;62:878–83.PubMedCrossRef
91.
Mirnikjoo B, Brown SE, Kim HF, et al. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem. 2001;276:10888–96.PubMedCrossRef
92.
Ikemoto A, Nitta A, Furukawa S, et al. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci Lett. 2000;285:99–102.PubMedCrossRef
93.
Sarsilmaz M, Songur A, Ozyurt H, et al. Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats’ corpus striatum. Prostaglandins Leukot Essent Fatty Acids. 2003;69:253–9.PubMedCrossRef
94.
Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006;84:112–20.PubMedCrossRef
95.
Puri BK. High-resolution magnetic resonance imaging sinc-interpolation-based subvoxel registration and semi-automated quantitative lateral ventricular morphology employing threshold computation and binary image creation in the study of fatty acid interventions in schizophrenia, depression, chronic fatigue syndrome and Huntington’s disease. Int Rev Psychiatry. 2006;18:149–54.PubMedCrossRef
Metadaten
Titel
Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment
verfasst von
Vladimir Lerner
Chanoch Miodownik
Publikationsdatum
01.08.2011
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 4/2011
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-011-0202-6

Weitere Artikel der Ausgabe 4/2011

Current Psychiatry Reports 4/2011 Zur Ausgabe

ReviewPaper

Prevention of Anxiety Disorders

ReviewPaper

Perceived Ugliness: An Update on Treatment-Relevant Aspects of Body Dysmorphic Disorder

CLINICAL TRIAL REPORT

What Can We Expect From Long-Acting Formulations for Schizophrenia?

ReviewPaper

Update on Repetitive Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Different Targets

Clinical Trial Report

Combining Sertraline and Naltrexone in the Treatment of Adults with Comorbid Depression and Alcohol Dependence

ReviewPaper

Update: Schizophrenia Across Cultures

Neu im Fachgebiet Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise